0.19
—
Close of 5 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Lyra Therapeutics
Its shares trade under the ticker LYRA. It has been listed since 1 May 2020. In the fiscal year to 31 December 2025, it reported revenue of $398,000 and a net loss of $28.9m. At that date it held total assets of $36.1m and shareholders' equity of −$10.7m.
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts. The company went IPO on 2020-05-01. The Company’s product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). LYR-210 is an anti-inflammatory implantable drug matrix based on its XTreo platform that is designed to locally elute mometasone furoate (MF) to the inflamed mucosal tissue for up to six months in surgically-naive CRS patients who fail medical management. The company has developed LYR-220 for use in CRS patients who continue to require treatment to manage CRS symptoms despite having had sinus surgery.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 May 2020
- Employees
- 38
- Website
- lyratherapeutics.com ↗
- Head office
- 480 ARSENAL WAY, WATERTOWN, MA, 02472
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Richard NiemanChief Medical Officer$1.4m
- Mr. James TobinLead Independent Director$100,669
- Ms. C. Ann MerrifieldIndependent Director$61,419
- Mr. W. Bradford SmithIndependent Director$72,169
- Dr. Nancy SnydermanIndependent Director$62,732
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 50
- Environment
- 51
- Social
- 71
- Governance
- 27
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Lyra Therapeutics has 38 employees focused on clinical-stage therapeutics in the Health Care sector.
- LYR-210 and LYR-220 are bioresorbable polymeric matrices for chronic rhinosinusitis treatment.
- The XTreo platform enables six months of continuous drug therapy in non-invasive procedures.
Weaknesses
- The company has only 38 employees for a clinical-stage therapeutics company.
- LYR-210 targets surgically-naive CRS patients who fail medical management.
- LYR-220 is for CRS patients who continue treatment after sinus surgery.
Opportunities
- The US market offers opportunities for chronic rhinosinusitis treatments.
- The XTreo platform could expand to other therapeutic areas.
- The company's IPO on 1 May 2020 provides capital for growth.
Threats
- The Health Care sector faces regulatory challenges for new drug approvals.
- Chronic rhinosinusitis treatments compete with existing medical management options.
- The company's small size may limit resources for clinical trials.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.